213 related articles for article (PubMed ID: 19487683)
21. Angiotensin receptor signaling and prostate tumor growth in mice.
Scott-Emuakpor J; Allot E; Johnson SA; Howard LE; Macias E; Freedland SJ; Gurley SB
J Exp Ther Oncol; 2017 Sep; 11(2):107-115. PubMed ID: 28976133
[TBL] [Abstract][Full Text] [Related]
22. The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis.
Königshoff M; Wilhelm A; Jahn A; Sedding D; Amarie OV; Eul B; Seeger W; Fink L; Günther A; Eickelberg O; Rose F
Am J Respir Cell Mol Biol; 2007 Dec; 37(6):640-50. PubMed ID: 17630322
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
[TBL] [Abstract][Full Text] [Related]
24. Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients.
Moreno-Muñoz D; de la Haba-Rodríguez JR; Conde F; López-Sánchez LM; Valverde A; Hernández V; Martínez A; Villar C; Gómez-España A; Porras I; Rodríguez-Ariza A; Aranda E
Eur J Clin Invest; 2015 Dec; 45(12):1325-32. PubMed ID: 26509357
[TBL] [Abstract][Full Text] [Related]
25. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
[TBL] [Abstract][Full Text] [Related]
26. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
[TBL] [Abstract][Full Text] [Related]
27. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
28. The Angiotensin II Type 1 Receptor Antagonist Losartan Affects NHE1-Dependent Melanoma Cell Behavior.
Olschewski DN; Hofschröer V; Nielsen N; Seidler DG; Schwab A; Stock C
Cell Physiol Biochem; 2018; 45(6):2560-2576. PubMed ID: 29558744
[TBL] [Abstract][Full Text] [Related]
29. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
30. Losartan treatment attenuates tumor-induced myocardial dysfunction.
Stevens SC; Velten M; Youtz DJ; Clark Y; Jing R; Reiser PJ; Bicer S; Devine RD; McCarthy DO; Wold LE
J Mol Cell Cardiol; 2015 Aug; 85():37-47. PubMed ID: 25988231
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin II promotes the progression of human gastric cancer.
Huang MM; Guo AB; Sun JF; Chen XL; Yin ZY
Mol Med Rep; 2014 Mar; 9(3):1056-60. PubMed ID: 24424956
[TBL] [Abstract][Full Text] [Related]
32. The role of angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model.
Koga H; Yang H; Haxhija EQ; Teitelbaum DH
Pediatr Surg Int; 2008 Dec; 24(12):1279-86. PubMed ID: 18989682
[TBL] [Abstract][Full Text] [Related]
33. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
34. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.
Shen Q; Uray IP; Li Y; Zhang Y; Hill J; Xu XC; Young MR; Gunther EJ; Hilsenbeck SG; Colburn NH; Chodosh LA; Brown PH
Cancer Prev Res (Phila); 2008 Jun; 1(1):45-55. PubMed ID: 19138935
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II type 1 (AT-1) receptor inhibition partially prevents the urodynamic and detrusor changes associated with bladder outlet obstruction: a mouse model.
Comiter C; Phull HS
BJU Int; 2012 Jun; 109(12):1841-6. PubMed ID: 21939491
[TBL] [Abstract][Full Text] [Related]
36. The impact of renin-angiotensin system, angiotensin І converting enzyme (insertion/deletion), and angiotensin ІІ type 1 receptor (A1166C) polymorphisms on breast cancer survival in Iran.
Namazi S; Daneshian A; Mohammadianpanah M; Jafari P; Ardeshir-Rouhani-Fard S; Nasirabadi S
Gene; 2013 Dec; 532(1):125-31. PubMed ID: 24055489
[TBL] [Abstract][Full Text] [Related]
37. AT1 receptor blockade delays postlactational mammary gland involution: a novel role for the renin angiotensin system.
Nahmod KA; Walther T; Cambados N; Fernandez N; Meiss R; Tappenbeck N; Wang Y; Raffo D; Simian M; Schwiebs A; Pozner RG; Fuxman Bass JI; Pozzi AG; Geffner JR; Kordon EC; Schere-Levy C
FASEB J; 2012 May; 26(5):1982-94. PubMed ID: 22286690
[TBL] [Abstract][Full Text] [Related]
38. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.
Ariazi EA; Clark GM; Mertz JE
Cancer Res; 2002 Nov; 62(22):6510-8. PubMed ID: 12438245
[TBL] [Abstract][Full Text] [Related]
39. Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan.
Bhuiyan MA; Hossain M; Nakamura T; Ozaki M; Nagatomo T
J Pharmacol Sci; 2010; 112(4):459-62. PubMed ID: 20308802
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
Saikawa S; Kaji K; Nishimura N; Seki K; Sato S; Nakanishi K; Kitagawa K; Kawaratani H; Kitade M; Moriya K; Namisaki T; Mitoro A; Yoshiji H
Cancer Lett; 2018 Oct; 434():120-129. PubMed ID: 30031758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
